Treating Metastatic NSCLC: Choosing the Best Treatment for Optimal Outcomes
A panel of oncology experts discusses treatment options, strategies, and patient care for metastatic NSCLC, with a focus on ALK and KRAS mutations.
EP. 1: Sarah’s Journey With ALK+ Metastatic NSCLC
A panel of experts review a case of a 55-year-old mom and high school teacher who received lorlatinib for ALK+ NSCLC with brain metastases.
EP. 2: The Role of Molecular Testing in Treatment Decisions for NSCLC
This video segment explores the critical role of biomarker testing in identifying patients with ALK-positive NSCLC, discussing the clinical characteristics that guide the use of ALK inhibitors and addressing challenges in implementing comprehensive molecular testing in community settings.
EP. 3: The Benefits of Lorlatinib for ALK+ NSCLC: CROWN Update
This video segment reviews the clinical evidence supporting lorlatinib as a first-line treatment for ALK-positive metastatic NSCLC, emphasizing key efficacy outcomes from the phase 3 CROWN trial.
EP. 4: Assessing Treatment Options for ALK+ NSCLC
This video segment provides an in-depth discussion on the first-line use of lorlatinib for ALK-positive metastatic NSCLC, including clinical evidence from the phase 3 CROWN trial, the broader therapeutic landscape and alternative strategies, real-world insights on lorlatinib's performance, and key considerations for selecting among ALK inhibitors based on patient-specific factors.
